Author name: Shamnad Basheer

I’ve been given to understand that Natco’s counsel presented arguments before the patent office today. However, it appears that most of the arguments were centered around the interlocutory application filed by Natco, opposing the move by the patent office to hear Roche/Pfizer. Tomorrow, the patent office will hear arguments in this regard from counsels representing Pfizer/Roche. It is only after they decide on this interlocutory application (i.e. that parties cannot be heard under section 92A) that the matter will be […]

Pursuant to our posts on the Natco’s application for a Doha Style Compulsory license to export two anti-cancer drugs patented by Roche/Pfizer, there have been some articles on this theme in the mainstream media. We bring you two of them in this post. For our earlier posts, see here (in particular see the exchange with Tahir Amin in the “comments” section of the blog post), and here. Tatum Anderson wrote a piece in IP Watch and Jonathan Allen reports on

Sarah Hiddleston from the Hindu reports on a hearing to decide whether or not India should issue its first compulsory license for the export of Pfizer’s Sunitnib and Roches’ Erlotinib to Nepal. We had blogged on this application earlier here, setting out the text of section 92A and the various legal issues involved with this compulsory licensing application. “The government is to consider whether or not it should allow its drugs companies to manufacture patented medicines for export to poor